Core Viewpoint - Candel Therapeutics, Inc. is actively engaging with investors through participation in multiple upcoming conferences, highlighting its focus on developing innovative immunotherapies for cancer treatment [1][2]. Group 1: Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating off-the-shelf multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [3]. - The company has developed two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [3]. Group 2: Product Development - Candel's lead product candidate, CAN-2409, has successfully completed phase 2a clinical trials for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is undergoing a pivotal phase 3 trial for localized prostate cancer [4]. - CAN-2409 has received several designations from the FDA, including Regenerative Medicine Advanced Therapy Designation for localized prostate cancer, and Fast Track Designation for both NSCLC and prostate cancer [4]. - The second lead product candidate, CAN-3110, is currently in a phase 1b clinical trial for recurrent high-grade glioma (rHGG) and has also received Fast Track and Orphan Drug Designations from the FDA [5]. Group 3: Upcoming Events - Candel Therapeutics will participate in the following investor conferences: - Citi's 2025 Biopharma Back to School Conference on September 3, 2025, at 9:00 AM ET [2]. - Cantor Global Healthcare Conference on September 4, 2025, at 8:00 AM ET [2]. - H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, at 7:00 AM ET [2]. - Live webcasts of these presentations will be available and archived for up to 90 days [2].

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis supports clear and rapid path to BLA Webcast today August 28th, at 11 am ET EMERYVILLE, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimm ...

BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium ...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Cantor Global Healthcare Conference 2025Date: Thursday, September 4, 2025Fireside Chat: 8:35 a.m. ETLocation: New York, NY H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Formal Presentation: 11:30 ...

Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ETNEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 - 5, 2025. The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET. A live webcast of the fireside chat will be available on the E ...

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025. The event, held at the Lotte New York Palace Hotel in New York City and virtually, features more than 550 corporate presentations from lea ...

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as foll ...

WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York. Morgan Stanley 23rd Annual Global Healthcare Conference, firesi ...

NEW HAVEN, Conn., Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September.2025 Wells Fargo Healthcare Confe ...

Core Viewpoint - Vanda Pharmaceuticals Inc. has received Orphan Drug Designation from the FDA for VGT-1849B, a selective JAK2 inhibitor aimed at treating polycythemia vera (PV) [1][5]. Group 1: Product Overview - VGT-1849B is a selective peptide nucleic acid-based JAK2 inhibitor designed to target JAK2 mRNA, thereby reducing JAK2 protein production and downstream signaling associated with PV [3][8]. - The prevalence of PV in the U.S. is estimated to affect 44 to 57 per 100,000 people, with over 95% of patients harboring the JAK2 V617F mutation [2][9]. - VGT-1849B utilizes a novel backbone chemistry, OliPass Peptide Nucleic Acid (OPNA), which enhances cell permeability and RNA affinity [2][8]. Group 2: Mechanism of Action - By selectively targeting JAK2 mRNA, VGT-1849B effectively reduces JAK2-driven cell proliferation and suppresses hematopoiesis, leading to decreased production of red blood cells, neutrophils, platelets, and lymphocytes [3][4]. - The drug aims to provide a favorable safety profile by avoiding off-target effects commonly associated with other JAK inhibitors [4]. Group 3: Market Context - Current JAK2 inhibitors on the market, such as Jakafi®, Inrebic®, Ojjaara®, and Vonjo®, are not solely selective to JAK2, which can lead to increased toxicity [4]. - If approved, VGT-1849B could offer targeted efficacy with an improved safety profile and convenient infrequent dosing, addressing a significant unmet medical need in the treatment of PV [5]. Group 4: Company Background - Vanda Pharmaceuticals Inc. is focused on developing innovative therapies to meet high unmet medical needs and improve patient lives [7].